Finally, the immunostimulant CXCL12 is negatively correlated with SPC25; if SPC25 expression is an effective indicator of prognosis in BC, CXCL12 might also serve as a useful immunotherapy biomarker by reflecting the status of the immune microenvironment in BC patients. Here, CXCL12 is linked to breast cancer.